Ghulam Mujtaba Ghumman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ghulam Mujtaba Ghumman has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Mohammed Taleb
9 shared publicationsSyed Sohail Ali
Department of Cardiology, Mercy Health Saint Vincent Medical Center, Toledo, Ohio, USA
8 shared publicationsJay Shah
Department of Cardiology, Mercy Saint Vincent Medical Center, Toledo, USA
7 shared publicationsHemindermeet Singh
Department of Cardiology, Mercy Saint Vincent Medical Center, Toledo, USA
5 shared publicationsKritika Luthra
Mercy Health St. Vincent's Medical Center, United States
5 shared publicationsAmeer Kabour
Toledo Cardiology Consultants, United States
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (39)
BATMAN-Assisted Valve-in-Valve TMVR With Planned Hemodynamic Support in Severe Pulmonary Hypertension
- 30 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (39)
Open AccessBATMAN-Assisted Valve-in-Valve TMVR With Planned Hemodynamic Support in Severe Pulmonary Hypertension
- Open Access
- 29 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5784-5792
A 25 year nationwide analysis of mortality trends from cerebrovascular diseases in patients with lung cancer (1999–2023)
Introduction: The two leading causes of death worldwide are lung cancer and cerebrovascular disease (CVD). Due to complications related to the disease and therapy, patients with lung cancer are much more likely to have a stroke, particularly within 2 years after diagnosis. Results are still poor despite medical advancements, underscoring the necessity of comprehensive prevention and care. Methods: ICD-10 codes for lung cancer (C34) and cerebrovascular illness (I60–I69) were used to evaluate mortality data from CDC WONDER (1999–2023). When both illnesses were listed on death certificates, deaths were counted. Sex, race/ethnicity, area, and urban/rural status were used to compute age adjusted mortality rates (AAMRs). Joinpoint regression was used to evaluate trends, and P < 0.05 was considered significant. Results: Overall AAMR for CVD and lung cancer decreased from 2.19 to 1.44 per 100 000 (APC: −2.9; P < 0.0001) between 1999 and 2015, subsequently increased to 1.71 in 2023 (APC: +2.8; P < 0.0001). From 3.08 in 1999 to 1.98 in 2023, men’s rates were continuously higher than women’s (1.59 to 1.49). The AAMR was highest among NH Black people (it peaked at 2.32 in 2023), followed by NH Whites (1.68) and Hispanics (0.69). Rural areas had higher AAMR than Urban areas. Alaska (2.57), Vermont (2.46), and Mississippi (2.46) had the highest state level burdens, while Utah (0.64) and New Mexico (0.86) had the lowest, while the South and Midwest region saw the sharpest recent rises. Conclusion: Lung cancer mortality from CVD increased until 2023 after decreasing until 2015. The U.S. South, rural areas, Black adults, and men had the biggest burden. To lower stroke mortality in patients with lung cancer, targeted interventions are required, with a focus on addressing racial and rural disparities in care, prevention, and access.
- 29 July 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5784-5792
Open AccessA 25 year nationwide analysis of mortality trends from cerebrovascular diseases in patients with lung cancer (1999–2023)
Introduction: The two leading causes of death worldwide are lung cancer and cerebrovascular disease (CVD). Due to complications related to the disease and therapy, patients with lung cancer are much more likely to have a stroke, particularly within 2 years after diagnosis. Results are still poor despite medical advancements, underscoring the necessity of comprehensive prevention and care. Methods: ICD-10 codes for lung cancer (C34) and cerebrovascular illness (I60–I69) were used to evaluate mortality data from CDC WONDER (1999–2023). When both illnesses were listed on death certificates, deaths were counted. Sex, race/ethnicity, area, and urban/rural status were used to compute age adjusted mortality rates (AAMRs). Joinpoint regression was used to evaluate trends, and P < 0.05 was considered significant. Results: Overall AAMR for CVD and lung cancer decreased from 2.19 to 1.44 per 100 000 (APC: −2.9; P < 0.0001) between 1999 and 2015, subsequently increased to 1.71 in 2023 (APC: +2.8; P < 0.0001). From 3.08 in 1999 to 1.98 in 2023, men’s rates were continuously higher than women’s (1.59 to 1.49). The AAMR was highest among NH Black people (it peaked at 2.32 in 2023), followed by NH Whites (1.68) and Hispanics (0.69). Rural areas had higher AAMR than Urban areas. Alaska (2.57), Vermont (2.46), and Mississippi (2.46) had the highest state level burdens, while Utah (0.64) and New Mexico (0.86) had the lowest, while the South and Midwest region saw the sharpest recent rises. Conclusion: Lung cancer mortality from CVD increased until 2023 after decreasing until 2015. The U.S. South, rural areas, Black adults, and men had the biggest burden. To lower stroke mortality in patients with lung cancer, targeted interventions are required, with a focus on addressing racial and rural disparities in care, prevention, and access.
- 15 July 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- p. 1-4
Snare-assisted bailout of an embolized Evolut FX transcatheter aortic valve replacement prosthesis using a valve-through-valve balloon-expandable implantation.
Transcatheter aortic valve replacement (TAVR) is now the standard of care for severe symptomatic aortic stenosis; however, rare procedural complications such as valve embolization can result in life-threatening consequences. We describe a case of intraprocedural embolization of a self-expanding Medtronic Evolut FX valve into the ascending aorta during deployment. The embolized prosthesis was stabilized with a snare and parked distal to the sinotubular junction. Because a second self-expanding valve could not be advanced across the displaced frame, a 23 mm balloon-expandable Edwards SAPIEN 3 Ultra RESILIA valve was successfully delivered through the embolized prosthesis and deployed in the native annulus. This cross-platform valve-through-valve bailout restored durable valve function without surgery and underscores the importance of procedural adaptability in managing complex TAVR complications.
- 15 July 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- p. 1-4
Snare-assisted bailout of an embolized Evolut FX transcatheter aortic valve replacement prosthesis using a valve-through-valve balloon-expandable implantation.
Transcatheter aortic valve replacement (TAVR) is now the standard of care for severe symptomatic aortic stenosis; however, rare procedural complications such as valve embolization can result in life-threatening consequences. We describe a case of intraprocedural embolization of a self-expanding Medtronic Evolut FX valve into the ascending aorta during deployment. The embolized prosthesis was stabilized with a snare and parked distal to the sinotubular junction. Because a second self-expanding valve could not be advanced across the displaced frame, a 23 mm balloon-expandable Edwards SAPIEN 3 Ultra RESILIA valve was successfully delivered through the embolized prosthesis and deployed in the native annulus. This cross-platform valve-through-valve bailout restored durable valve function without surgery and underscores the importance of procedural adaptability in managing complex TAVR complications.
- Open Access
- 25 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (18) , 107641
Percutaneous Aspiration for IVDU–Associated Infective Endocarditis
- 25 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (18) , 107641
Open AccessPercutaneous Aspiration for IVDU–Associated Infective Endocarditis
- 1 January 2026
- Published by e-Century Publishing Corporation in American Journal of Cardiovascular Disease
- Vol. 16 (1) , 63-72
Outcomes of Watchman device implantation in atrial fibrillation patients contraindicated for long-term anticoagulation: a single-center experience
Background: Left atrial appendage occlusion (LAAO) using the Watchman device is an established strategy for stroke prevention in atrial fibrillation (AF) patients at high thromboembolic risk who cannot tolerate long-term oral anticoagulation (OAC). Objectives: To evaluate short-term clinical and echocardiographic outcomes of Watchman implantation in AF patients with contraindications to long-term OAC. Methods: We conducted a retrospective single-center study of AF patients who underwent Watchman implantation between September 01, 2023, and March 01, 2025. Baseline demographics, comorbidities, procedural characteristics, complications, antithrombotic strategies, and 45-day outcomes were analyzed. Outcomes were compared between patients with and without follow-up TEE. Data were analyzed using SAS v9.4. All tests were two-tailed, and a p-value 5 mm), and none had device-related thrombus. Clinical outcomes included one hemorrhagic stroke (1.1%) and eight rehospitalizations (7.6%, 95% CI 3.4-14.5%), unrelated to the device. No ischemic strokes were observed. Conclusion: Watchman implantation achieved a 100% success rate with low complication rates and favorable short-term clinical and echocardiographic outcomes in AF patients contraindicated for long-term anticoagulation.
- 1 January 2026
- Published by e-Century Publishing Corporation in American Journal of Cardiovascular Disease
- Vol. 16 (1) , 63-72
Outcomes of Watchman device implantation in atrial fibrillation patients contraindicated for long-term anticoagulation: a single-center experience
Background: Left atrial appendage occlusion (LAAO) using the Watchman device is an established strategy for stroke prevention in atrial fibrillation (AF) patients at high thromboembolic risk who cannot tolerate long-term oral anticoagulation (OAC). Objectives: To evaluate short-term clinical and echocardiographic outcomes of Watchman implantation in AF patients with contraindications to long-term OAC. Methods: We conducted a retrospective single-center study of AF patients who underwent Watchman implantation between September 01, 2023, and March 01, 2025. Baseline demographics, comorbidities, procedural characteristics, complications, antithrombotic strategies, and 45-day outcomes were analyzed. Outcomes were compared between patients with and without follow-up TEE. Data were analyzed using SAS v9.4. All tests were two-tailed, and a p-value 5 mm), and none had device-related thrombus. Clinical outcomes included one hemorrhagic stroke (1.1%) and eight rehospitalizations (7.6%, 95% CI 3.4-14.5%), unrelated to the device. No ischemic strokes were observed. Conclusion: Watchman implantation achieved a 100% success rate with low complication rates and favorable short-term clinical and echocardiographic outcomes in AF patients contraindicated for long-term anticoagulation.
- Open Access
- 18 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 401-411
Smart bioactive hydrogels for myocardial infarction repair: a multifunctional approach integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing
Background: Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, necessitating advanced therapeutic strategies for cardiac repair. Conventional treatments often fail to restore cardiac function effectively, highlighting the need for innovative biomaterials. Smart bioactive hydrogels have emerged as promising candidates due to their ability to provide structural support, controlled drug delivery, electroconductivity, and real-time biosensing capabilities. Objective: This review explores the multifunctional role of smart bioactive hydrogels in MI repair, focusing on their stimuli-responsive drug delivery, electroconductive properties, and biosensing potential. Methods: This narrative review synthesized recent advances in multifunctional smart bioactive hydrogels for MI repair, focusing on systems integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar for studies published between 2010 and 2025 using relevant keywords. Articles were included if they addressed hydrogel-based platforms featuring at least one of the following: responsive drug release (e.g., pH, temperature, and enzymatic), conductive components (e.g., carbon nanotubes and graphene), or embedded biosensing technologies. Studies limited to conventional hydrogels without multifunctionality were excluded. Relevant data were extracted and thematically categorized by material composition, functional properties, regenerative potential, and translational applicability, with emphasis on preclinical cardiac models. No quantitative synthesis was performed due to heterogeneity across study designs. Results: Smart bioactive hydrogels have demonstrated significant potential for MI repair by integrating stimuli-responsive drug delivery, electroconductivity, and biosensing within a single therapeutic platform. pH-, ROS-, and enzyme-sensitive systems enable localized, on-demand release of angiogenic factors or cardioprotective drugs, leading to 20–45% infarct size reduction and 1.5–2.3-fold increases in neovascular density in preclinical models. Incorporation of conductive materials such as graphene oxide (GO), polypyrrole, or carbon nanotubes (CNT) has been shown to restore electrical coupling, improve connexin-43 expression, and enhance left ventricular ejection fraction by 8–15%, while narrowing QRS complex duration by ~15 ms in large-animal studies. Emerging biosensing-enabled hydrogels permit real-time monitoring of local biochemical cues, such as pH, oxygen levels, and inflammatory cytokines, maintaining stable signal fidelity for up to 4 weeks without adverse tissue reactions. Advances in 3D/4D bioprinting now allow spatially patterned integration of these functionalities, enabling region-specific therapeutic release and conductivity optimization. Collectively, these multifunctional hydrogels exhibit superior regenerative outcomes compared to conventional scaffolds and hold strong translational promise, although variability in experimental design, lack of standardized endpoints, and limited long-term clinical data remain challenges to widespread adoption. Conclusion: Smart bioactive hydrogels represent a transformative approach in MI repair by combining structural support with multifunctional properties. Their ability to deliver therapeutics on demand, enhance electroconductivity, and enable real-time biosensing offers new possibilities for precision cardiac medicine.
- 18 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 401-411
Open AccessSmart bioactive hydrogels for myocardial infarction repair: a multifunctional approach integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing
Background: Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, necessitating advanced therapeutic strategies for cardiac repair. Conventional treatments often fail to restore cardiac function effectively, highlighting the need for innovative biomaterials. Smart bioactive hydrogels have emerged as promising candidates due to their ability to provide structural support, controlled drug delivery, electroconductivity, and real-time biosensing capabilities. Objective: This review explores the multifunctional role of smart bioactive hydrogels in MI repair, focusing on their stimuli-responsive drug delivery, electroconductive properties, and biosensing potential. Methods: This narrative review synthesized recent advances in multifunctional smart bioactive hydrogels for MI repair, focusing on systems integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar for studies published between 2010 and 2025 using relevant keywords. Articles were included if they addressed hydrogel-based platforms featuring at least one of the following: responsive drug release (e.g., pH, temperature, and enzymatic), conductive components (e.g., carbon nanotubes and graphene), or embedded biosensing technologies. Studies limited to conventional hydrogels without multifunctionality were excluded. Relevant data were extracted and thematically categorized by material composition, functional properties, regenerative potential, and translational applicability, with emphasis on preclinical cardiac models. No quantitative synthesis was performed due to heterogeneity across study designs. Results: Smart bioactive hydrogels have demonstrated significant potential for MI repair by integrating stimuli-responsive drug delivery, electroconductivity, and biosensing within a single therapeutic platform. pH-, ROS-, and enzyme-sensitive systems enable localized, on-demand release of angiogenic factors or cardioprotective drugs, leading to 20–45% infarct size reduction and 1.5–2.3-fold increases in neovascular density in preclinical models. Incorporation of conductive materials such as graphene oxide (GO), polypyrrole, or carbon nanotubes (CNT) has been shown to restore electrical coupling, improve connexin-43 expression, and enhance left ventricular ejection fraction by 8–15%, while narrowing QRS complex duration by ~15 ms in large-animal studies. Emerging biosensing-enabled hydrogels permit real-time monitoring of local biochemical cues, such as pH, oxygen levels, and inflammatory cytokines, maintaining stable signal fidelity for up to 4 weeks without adverse tissue reactions. Advances in 3D/4D bioprinting now allow spatially patterned integration of these functionalities, enabling region-specific therapeutic release and conductivity optimization. Collectively, these multifunctional hydrogels exhibit superior regenerative outcomes compared to conventional scaffolds and hold strong translational promise, although variability in experimental design, lack of standardized endpoints, and limited long-term clinical data remain challenges to widespread adoption. Conclusion: Smart bioactive hydrogels represent a transformative approach in MI repair by combining structural support with multifunctional properties. Their ability to deliver therapeutics on demand, enhance electroconductivity, and enable real-time biosensing offers new possibilities for precision cardiac medicine.
- 19 November 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (2) , 345-348
Transcatheter Aortic Valve Replacement in Patients With Severe Rheumatic Aortic Stenosis: A Proportional Meta‐Analysis
- 19 November 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (2) , 345-348
Transcatheter Aortic Valve Replacement in Patients With Severe Rheumatic Aortic Stenosis: A Proportional Meta‐Analysis
- Open Access
- 30 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e70564
Dilemma of ST-Segment Elevation and Subarachnoid Hemorrhage: A Case Report and Literature Review
Acute ST-segment elevation myocardial infarction (STEMI) occurs due to occlusion of one or more coronary arteries causing myocardial injury. It is a medical emergency and requires prompt diagnosis and intervention. Transient ST-segment elevation can occur due to coronary vasospasm, and their association has been reported with subarachnoid hemorrhage. We present a distinct case of ST-segment elevations in inferior leads with reciprocal ST-depressions in lateral leads, indicating STEMI that leads to complete heart block and ventricular fibrillation cardiac arrest in a patient with subarachnoid hemorrhage. The coronary angiogram was negative for any obstructive coronary artery disease.
- 30 September 2024
- Published by Springer Nature in Cureus
- Vol. 16 (9) , e70564
Open AccessDilemma of ST-Segment Elevation and Subarachnoid Hemorrhage: A Case Report and Literature Review
Acute ST-segment elevation myocardial infarction (STEMI) occurs due to occlusion of one or more coronary arteries causing myocardial injury. It is a medical emergency and requires prompt diagnosis and intervention. Transient ST-segment elevation can occur due to coronary vasospasm, and their association has been reported with subarachnoid hemorrhage. We present a distinct case of ST-segment elevations in inferior leads with reciprocal ST-depressions in lateral leads, indicating STEMI that leads to complete heart block and ventricular fibrillation cardiac arrest in a patient with subarachnoid hemorrhage. The coronary angiogram was negative for any obstructive coronary artery disease.
- 31 July 2023
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 23 (5) , 547-558
Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review
Background Pemafibrate is a novel fibrate class drug that is a highly potent and selective agonist of peroxisome proliferator-activated receptor α (PPARα). We performed the first ever network meta-analysis containing the largest ever group of patients to test the efficacy of pemafibrate in improving lipid levels compared with fenofibrate and placebo in patients with dyslipidemia. Methods Potentially relevant clinical trials were identified in Medline, PubMed, Embase, clinicaltrials.gov, and Cochrane Controlled Trials registry. Nine randomized controlled trials met the inclusion criteria out of 40 potentially available articles. The primary effect outcome was a change in the levels of triglycerides (TG), high-density lipoproteins (HDL), or low-density lipoproteins (LDL) before and after the treatment. Results A total of 12,359 subjects were included. The mean patient age was 54.73 (years), the mean ratio for female patients was 18.75%, and the mean examination period was 14.22 weeks. The dose for pemafibrate included in our study was 0.1, 0.2, or 0.4 mg twice daily, whereas the dose for fenofibrate was 100 mg/day. Data showed a significant reduction in TG and a mild increase in HDL levels across the pemafibrate group at different doses and fenofibrate 100 mg group (with greatest effect observed with pemafibrate 0.1 mg twice daily). A mild increase in LDL was also observed in all groups, but the increase in LDL in the 0.1 mg twice daily dose group was statistically insignificant. Conclusion Pemafibrate 0.1 mg twice daily dose led to highest reduction in TG levels and the highest increase in HDL levels compared with other doses of pemafibrate, fenofibrate, and placebo.
- 31 July 2023
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 23 (5) , 547-558
Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review
Background Pemafibrate is a novel fibrate class drug that is a highly potent and selective agonist of peroxisome proliferator-activated receptor α (PPARα). We performed the first ever network meta-analysis containing the largest ever group of patients to test the efficacy of pemafibrate in improving lipid levels compared with fenofibrate and placebo in patients with dyslipidemia. Methods Potentially relevant clinical trials were identified in Medline, PubMed, Embase, clinicaltrials.gov, and Cochrane Controlled Trials registry. Nine randomized controlled trials met the inclusion criteria out of 40 potentially available articles. The primary effect outcome was a change in the levels of triglycerides (TG), high-density lipoproteins (HDL), or low-density lipoproteins (LDL) before and after the treatment. Results A total of 12,359 subjects were included. The mean patient age was 54.73 (years), the mean ratio for female patients was 18.75%, and the mean examination period was 14.22 weeks. The dose for pemafibrate included in our study was 0.1, 0.2, or 0.4 mg twice daily, whereas the dose for fenofibrate was 100 mg/day. Data showed a significant reduction in TG and a mild increase in HDL levels across the pemafibrate group at different doses and fenofibrate 100 mg group (with greatest effect observed with pemafibrate 0.1 mg twice daily). A mild increase in LDL was also observed in all groups, but the increase in LDL in the 0.1 mg twice daily dose group was statistically insignificant. Conclusion Pemafibrate 0.1 mg twice daily dose led to highest reduction in TG levels and the highest increase in HDL levels compared with other doses of pemafibrate, fenofibrate, and placebo.
- Open Access
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100848
C-58 | The In-Hospital Outcomes of Atherectomy for Peripheral Arterial Disease Among Obese and Non-Obese Patients: An Insight from the National Inpatient Sample Database
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100848
Open AccessC-58 | The In-Hospital Outcomes of Atherectomy for Peripheral Arterial Disease Among Obese and Non-Obese Patients: An Insight from the National Inpatient Sample Database